Phase II Dose Titration Study in Patients With Neuropathic Pain

PHASE2CompletedINTERVENTIONAL
Enrollment

272

Participants

Timeline

Start Date

May 31, 2004

Primary Completion Date

April 30, 2007

Conditions
Neuropathic Pain
Interventions
DRUG

Ralfinamide

Oral tablets administered at rising doses of 80 - 320 mg/day

Trial Locations (47)

Unknown

Universitatsklinik Fur Neurologie, Graz

Universitatsklinik Fur Neurologie, Innsbruck

LKH, Klagenfurt

General Hospital AKH, Vienna

Fakultni nemocnice u svate' Anny v Brne, Brno

Fakultni nemocnice Brno, Brno-Bhunice

University Hospital Olomouc, Olomouc

Univercity Hospital Pilsen, Pizen

Fakultni Thomayerova nemocnices poliklinikou, Prague

Na Homolce Hospital, Prague

Neurology Centre, Ahmedabad

M.S. Ramaiah Medical, Bangalore

R.S. R'S Trinity Acute Care Hospital, Chennai

Sri Ramachandra medical College, Chennai

Care Hospital, Hyderabad

Chowpatty Medical Centre, Mumbai

Brain and Mind Institute, Nagpur

Apollo Hospital, Pradesh

Brain Waves Clinic, Pune

Vijaya Health Centre, Vadapalani

Ospedali Riuniti di Bergamo, Bergamo

Ce. S.I. Fondazione Universitaria, Chieti

Ospedale Clinicizzato Universitario SS. Annunziata, Chieti

Arcispedale Sant'Anna, Ferrara

Azienda Ospedaliera San Martino, Genova

Universita degli Studi di Genova, Genova

Ospedale Luigi Sacco, Grassi

Ospedale Civile Umberto I, Mestre

Ospedale San Raffaele, Milan

Istituto Scientifico di Riabilazione di Montescano, Montescano

Policlinico Universitario Federico II, Napoli

UCADH, Pavia

Presidio Ospedaliero Monteluce, Perugia

Universita degli Studi di Roma, Roma

Policlinico G.B. Rossi, Verona

Centrum Medyczne Osteomed, Bialobrzeska

Centrum Kliniczno Badawcze, Elblag

Wojewodzki Szpiyal Spejalistyczny, Gdansk

Center Of Clinical Neurology, Krakow

Osrodek Baden Klinicznych, Lublin

Wojskowy Instytut Medyczny, Warsaw

Wroclaw Medical University, Wroclaw

Oddzial Neurologiczny, Zgierz

Gartnavel General Hospital, Glasgow

Barta and The London NHS Trust, London

Kings College Hospital, London

Solihull Hospital, West Midlands

Sponsors
All Listed Sponsors
lead

Newron Pharmaceuticals SPA

INDUSTRY

NCT00736151 - Phase II Dose Titration Study in Patients With Neuropathic Pain | Biotech Hunter | Biotech Hunter